Regulation of p53 in response to DNA damage
The DOI matches its Crossref record; 128 of the 128 references it cites were found in a registry or an index.
Abstract
Activation of p53 can occur in response to a number of cellular stresses, including DNA damage, hypoxia and nucleotide deprivation. Several forms of DNA damage have been shown to activate p53, including those generated by ionising radiation (IR), radio-mimetic drugs, ultraviolet light (UV) and chemicals such as methyl methane sulfonate (MMS). Under normal conditions, p53 levels are maintained at a low state by virtue of the extremely short-half life of the polypeptide. In addition to this, p53 normally exists in an largely inactive state that is relatively inefficient at binding to DNA and activating transcription. Activation of p53 in response to DNA damage is associated with a rapid increase in its levels and with an increased ability of p53 to bind DNA and mediate transcriptional activation. This then leads to the activation of a number of genes whose products trigger cell-cycle arrest, apoptosis, or DNA repair. Recent work has suggested that this regulation is brought about largely through DNA damage triggering a series of phosphorylation, de-phosphorylation and acetylation events on the p53 polypeptide. Here, we discuss the nature of these modifications, the enzymes that bring them about, and how changes in p53 modification lead to p53 activation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“UV-induced phosphorylation at Serine 15 increased p53 stability and protein level that associated with DNA damage [61].”
From Ultraviolet Radiation‐Induced Skin Aging: The Role of DNA Damage and Oxidative Stress in Epidermal Stem Cell Damage Mediated Skin Aging (2016) · cites this paper as [61]
In the citing paper
“Under normal conditions, cellular p53 protein levels are very low owing to strict control by its negative regulators MDM2 and MDMX, which promote p53 degradation through ubiquitination.27,28”
From Targeting p53 pathways: mechanisms, structures, and advances in therapy (2023) · cites this paper as [28]
Citations
Cites
p53, the cellular gatekeeper for growth and division
Levine, A. J. (1997) · Cell · doi:10.1016/s0092-8674(00)81871-1 · Cited by 7,693
Mdm2 promotes the rapid degradation of p53
Haupt, Y., Maya, R., Kazaz, A., & Oren, M. (1997) · Nature · doi:10.1038/387296a0 · Cited by 4,506 · cited 1×
“Notably, several recent reports have provided data consistent with a model in which Mdm2 interacts with p53 in undamaged cells and targets it for ubiquitin-mediated degradation (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997; Fuchs et al., 1998).”
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 4,296
Regulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 1×
“Notably, several recent reports have provided data consistent with a model in which Mdm2 interacts with p53 in undamaged cells and targets it for ubiquitin-mediated degradation (Haupt et al., 1997; Honda et al., 1997; Kubbutat et al., 1997; Midgley and Lane, 1997; Fuchs et al., 1998).”
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 2×
“Interaction of Mdm2 with this N-terminal region of p53 has been demonstrated to inhibit the ability of p53 to activate transcription (Momand et al., 1992; Oliner et al., 1993).”
BackgroundKastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047 · cited 1×
“Initial clues suggesting that ATM may be involved in regulation of p53 in response to DNA damage came from observations that cell cycle checkpoint controls and up-regulation of p53 in response to IR are defective in A-T cells (Kastan et al., 1992; Khanna and Lavin, 1993; Canman et al., 1994).”
BackgroundHistone acetylation in chromatin structure and transcription
Grunstein, M. (1997) · Nature · doi:10.1038/38664 · Cited by 2,884 · cited 1×
“Further support for this idea has been provided by the demonstration that certain histone acetyl-transferase (HAT) enzymes correspond to key transcriptional coactivators, such as CBP/p300 and PCAF (for reviews see Grunstein, 1997; Kouzarides, 1999).”
BackgroundA Single Ataxia Telangiectasia Gene with a Product Similar to PI-3 Kinase
Savitsky, K., Bar-Shira, A., Gilad, S., Rotman, G., Ziv, Y., Vanagaite, L., Tagle, D. A., Smith, S., Uziel, T., Sfez, S., et al. (1995) · Science · doi:10.1126/science.7792600 · Cited by 2,785 · cited 1×
“The gene mutated in ataxia-telangiectasia patients was mapped to human chromosome 11q2223, and the gene, termed ATM, has been cloned (Gatti et al., 1988; Savitsky et al., 1995).”
BackgroundActivation of p53 Sequence-Specific DNA Binding by Acetylation of the p53 C-Terminal Domain
Gu, W., & Roeder, R. G. (1997) · Cell · doi:10.1016/s0092-8674(00)80521-8 · Cited by 2,559 · cited 2×
“Thus, in addition to potentially playing a role in acetylating histones at p53-dependent promoters, CBP/p300 has been shown to be able to acetylate p53 at lysine-373 and lysine-382, whilst PCAF can acetylate p53 at lysine-320 (Gu and Roeder, 1997; Sakaguchi, 1998; Liu et al., 1999).”
BackgroundKo, L. J., & Prives, C. (1996) · Genes & Development · doi:10.1101/gad.10.9.1054 · Cited by 2,344 · cited 4×
“Elevated levels of p21 then inhibit the cyclin E/cdk2 and cyclin A/cdk2 kinases, thus preventing these kinases from promoting cell cycle progression (for review, see Ko and Prives, 1996; Levine, 1997).”
BackgroundInfluential
Research works printed but not linked: 3
- Lakin ND, Hann BC and Jackson SP. . 1999 Oncogene in press.
- Lees-Miller SP, Sakaguchi K, Ullrich SJ, Appella E and Anderson CW. . 1992 Mol. Cell. Biol. 12: 5041–5049. · doi:10.1128/mcb.12.11.5041-5049.1992 · Paper page
- Maltzman W and Czyzyk L. . 1984 Mol. Cell. Biol. 4: 1689–1694. · DOI · Paper page
Cited by
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
“Intracellular factors that may inhibit such an activation of p53 include overexpression of the negative feedback regulator Mdm2 and downregulation of the moderator of Mdm2, p14ARF (Fritsche et al., 1993; Shieh et al., 1997; Lakin and Jackson, 1999; Meek, 1999; Deng et al., 2002).”
BackgroundRegulation of the G2/M transition by p53
Taylor, W. R., & Stark, G. R. (2001) · Oncogene · doi:10.1038/sj.onc.1204252 · Cited by 1,559
“Phosphorylation of the amino-terminal region of p53 causes it to accumulate and stimulates its ability to bind to speci®c DNA sequences, essential steps in activating p53 in response to stress (Lakin and Jackson, 1999).”
BackgroundA large-scale RNAi screen in human cells identifies new components of the p53 pathway
Berns, K., Hijmans, E. M., Mullenders, J., Brummelkamp, T. R., Velds, A., Heimerikx, M., Kerkhoven, R. M., Madiredjo, M., Nijkamp, W., Weigelt, B., et al. (2004) · Nature · doi:10.1038/nature02371 · Cited by 1,065
“Figure 2d shows that exposure of U2-OS cells to ionizing radiation (IR) causes these cells to withdraw from S phase and arrest both in the G1 phase of the cell cycle (a p53-dependent proces”
Dynamics of the p53-Mdm2 feedback loop in individual cells
Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A. J., Elowitz, M. B., & Alon, U. (2004) · Nature Genetics · doi:10.1038/ng1293 · Cited by 1,013
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
“and MDMX, which promote p53 degradation through ubiquitination.(27,28) When cells are exposed to internal and external stresses, including DNA damage, hypoxia, nutrient deprivation, and cancer cell risk, p53 ubiquitination is inhibited, triggering a rapid increase in intracellular p53 protein levels.”
BackgroundExploiting senescence for the treatment of cancer
Wang, L., Lankhorst, L., & Bernards, R. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00450-9 · Cited by 867
Cellular stress response and apoptosis in cancer therapy
Herr, I., & Debatin, K.-M. (2001) · Blood · doi:10.1182/blood.v98.9.2603 · Cited by 800
An atlas of substrate specificities for the human serine/threonine kinome
Johnson, J. L., Yaron, T. M., Huntsman, E. M., Kerelsky, A., Song, J., Regev, A., Lin, T.-Y., Liberatore, K., Cizin, D. M., Cohen, B. M., et al. (2023) · Nature · doi:10.1038/s41586-022-05575-3 · Cited by 728
Barlev, N. A., Liu, L., Chehab, N. H., Mansfield, K., Harris, K. G., Halazonetis, T. D., & Berger, S. L. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00414-2 · Cited by 710
The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions
Borner, C. (2003) · Molecular Immunology · doi:10.1016/s0161-5890(02)00252-3 · Cited by 703
The complexity of p53 stabilization and activation
Lavin, M. F., & Gueven, N. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401925 · Cited by 701
“The major modifications to p53 in response to stress are located at the N-terminus of the molecule, a region responsible for the transactivation capacity of p53 and where interaction occurs with MDM2, and in the C-terminal regulatory domain.(10) These post-translational modifications include phosphorylation, acetylati…”
BackgroundOscillations and variability in the p53 system
Geva‐Zatorsky, N., Rosenfeld, N., Itzkovitz, S., Milo, R., Sigal, A., Dekel, E., Yarnitzky, T., Liron, Y., Polak, P., Lahav, G., et al. (2006) · Molecular Systems Biology · doi:10.1038/msb4100068 · Cited by 653
The role of p53 in cancer drug resistance and targeted chemotherapy
Hientz, K., Mohr, A., Bhakta-Guha, D., & Efferth, T. (2017) · Oncotarget · doi:10.18632/oncotarget.13475 · Cited by 587
“Thus, the cellular levels of p53 and its inhibitor MDM2 are in turn, mutually controlled by negative feedback loop [9-11, 28, 30], wherein MDM2 downregulates p53 and p53 upregulates MDM2.”
BackgroundThe molecular biology of cancer
Bertram, J. S. (2000) · Molecular Aspects of Medicine · doi:10.1016/s0098-2997(00)00007-8 · Cited by 585
tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors
Berghmans, S., Murphey, R. D., Wienholds, E., Neuberg, D., Kutok, J. L., Fletcher, C. D. M., Morris, J. P., Liu, T. X., Schulte-Merker, S., Kanki, J. P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406252102 · Cited by 597
Cancer Metabolism: Phenotype, Signaling and Therapeutic Targets
Park, J. H., Pyun, W. Y., & Park, H. W. (2020) · Cells · doi:10.3390/cells9102308 · Cited by 548
DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme?
Durocher, D., & Jackson, S. P. (2001) · Current Opinion in Cell Biology · doi:10.1016/s0955-0674(00)00201-5 · Cited by 500
Self-citationEvaluation of the use of therapeutic peptides for cancer treatment
Marqus, S., Pirogova, E., & Piva, T. J. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0328-x · Cited by 512
“Its levels rise in response to cellular stresses such as DNA damage [208] and if there is a significant damage then it promotes the cell to undergo apoptosis [209].”
BackgroundAbegglen, L. M., Caulin, A. F., Chan, A., Lee, K., Robinson, R., Campbell, M. S., Kiso, W. K., Schmitt, D. L., Waddell, P. J., Bhaskara, S., et al. (2015) · JAMA · doi:10.1001/jama.2015.13134 · Cited by 485
“Consistent with previous evidence that increasing TP53 gene dosage increases transcriptional regulation of p53 target genes, 17,27 apoptotic rates in lymphocytes increased proportionally among patients with LFS (1 TP53 functioning allele), human controls (2 TP53 alleles), and elephants (40 TP53…”
Reversible centriole depletion with an inhibitor of Polo-like kinase 4
Wong, Y. L., Anzola, J. V., Davis, R. L., Yoon, M., Motamedi, A., Kroll, A., Seo, C. P., Hsia, J. E., Kim, S. K., Mitchell, J. W., et al. (2015) · Science · doi:10.1126/science.aaa5111 · Cited by 473
Ellisen, L. W., Ramsayer, K. D., Johannessen, C. M., Yang, A., Beppu, H., Minda, K., Oliner, J. D., McKeon, F., & Haber, D. A. (2002) · Molecular Cell · doi:10.1016/s1097-2765(02)00706-2 · Cited by 474
Drosophila p53 Binds a Damage Response Element at the reaper Locus
Brodsky, M. H., Nordstrom, W., Tsang, G., Kwan, E., Rubin, G. M., & Abrams, J. M. (2000) · Cell · doi:10.1016/s0092-8674(00)80627-3 · Cited by 473
“In this report, we use Dmp53 and Hp53 to distinguish between the Drosophila activity following DNA damage (Lakin and Jackson, 1999).”
MethodWRN helicase is a synthetic lethal target in microsatellite unstable cancers
Chan, E. M., Shibue, T., McFarland, J. M., Gaeta, B., Ghandi, M., Dumont, N., Gonzalez, A., McPartlan, J. S., Li, T., Zhang, Y., et al. (2019) · Nature · doi:10.1038/s41586-019-1102-x · Cited by 458
Homologous recombinational repair of DNA ensures mammalian chromosome stability
Thompson, L. H., & Schild, D. (2001) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(01)00115-4 · Cited by 429
Lopez-Gonzalez, R., Lu, Y., Gendron, T. F., Karydas, A., Tran, H., Yang, D., Petrucelli, L., Miller, B. L., Almeida, S., & Gao, F.-B. (2016) · Neuron · doi:10.1016/j.neuron.2016.09.015 · Cited by 419
“The p53mRNA levels were the same in both cultures (Figure S2C), suggesting that the increase in p53 protein reflects posttranslational regulation, as in other cell types (Lakin and Jackson, 1999).”
InfluentialThe endless tale of non-homologous end-joining
Weterings, E., & Chen, D. J. (2008) · Cell Research · doi:10.1038/cr.2008.3 · Cited by 418
Covalent Modification of p73α by SUMO-1
Minty, A., Dumont, X., Kaghad, M., & Caput, D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m004293200 · Cited by 388
Chk2 activates E2F-1 in response to DNA damage
Stevens, C., Smith, L., & La Thangue, N. B. (2003) · Nature Cell Biology · doi:10.1038/ncb974 · Cited by 385
“, the p53 response has been ascribed to both cell cycle arrest and apoptosi”
BackgroundCaricasole, A., Copani, A., Caraci, F., Aronica, E., Rozemuller, A. J., Caruso, A., Storto, M., Gaviraghi, G., Terstappen, G. C., & Nicoletti, F. (2004) · The Journal of Neuroscience · doi:10.1523/jneurosci.1381-04.2004 · Cited by 398
“DNA damage associated with p53 expression may be a point of convergence of multiple intracellular pathways related to AP toxicity (Zhang et al., 2002). p53 induces a number of genes that promote either DNA repair or apoptotic death (Lakin and Jackson , 1999; Shen and White, 2001).”
BackgroundAgami, R., & Bernards, R. (2000) · Cell · doi:10.1016/s0092-8674(00)00010-6 · Cited by 390
“Introduction for G1 arrest (reviewed in Lakin and Jackson, 1999), apoptosis (reviewed in Sionov and Haupt, 1999), and to Cyclins are essential components of the cell cycle masustain arrest of cells prior to M phase (Bunz et al., chinery.”
BackgroundThe prolyl isomerase Pin1 is a regulator of p53 in genotoxic response
Zheng, H., You, H., Zhou, X. Z., Murray, S. A., Uchida, T., Wulf, G., Gu, L., Tang, X., Lu, K. P., & Xiao, Z.-X. J. (2002) · Nature · doi:10.1038/nature01116 · Cited by 383
“jpg" NDATA ITEM> ]> p53 is activated in response to various genotoxic stresses resulting in cell cycle arrest or apoptosi”
BackgroundPathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases
Di Girolamo, N., Chui, J., Coroneo, M. T., & Wakefield, D. (2004) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2004.02.002 · Cited by 368
Panich, U., Sittithumcharee, G., Rathviboon, N., & Jirawatnotai, S. (2016) · Stem Cells International · doi:10.1155/2016/7370642 · Cited by 374
“UV-induced phosphorylation at Serine 15 increased p53 stability and protein level that associated with DNA damage [61].”
Checking out the G2/M transition
Smits, V. A. J., & Medema, R. H. (2001) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(01)00204-4 · Cited by 355
Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response
Beli, P., Lukashchuk, N., Wagner, S. A., Weinert, B. T., Olsen, J. V., Baskcomb, L., Mann, M., Jackson, S. P., & Choudhary, C. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.01.026 · Cited by 330
“This group of proteins contains well-known targets of the key tumor suppressor and DNA damage-activated transcription factor p53 (Lakin and Jackson, 1999), such as Sestrin-1, CDKN1A, CKAP2, and P53R2 (Table S3).”
Self-citationp53 Acetylation: Regulation and Consequences
Reed, S., & Quelle, D. (2014) · Cancers · doi:10.3390/cancers7010030 · Cited by 332
“Phosphorylation of S15, T18, S20 and S37, and/or multisite phosphorylation of p53 promotes the recruitment of p300/CBP [141,163–170], while PCAF-p53 binding is enhanced by S33 and S37 phosphorylation [51].”
BackgroundWoods, D. B., & Vousden, K. H. (2001) · Experimental Cell Research · doi:10.1006/excr.2000.5141 · Cited by 319
Activation and activities of the p53 tumour suppressor protein
Bálint, É., & Vousden, K. H. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2128 · Cited by 313
“Many stress signals, including some DNA-damaging agents, modulate p53 and MDM2 activity through induction of kinases (Lakin and Jackson, 1999).”
BackgroundA DNA Damage–Induced p53 Serine 392 Kinase Complex Contains CK2, hSpt16, and SSRP1
Keller, D. M., Zeng, X., Wang, Y., Zhang, Q. H., Kapoor, M., Shu, H., Goodman, R., Lozano, G., Zhao, Y., & Lu, H. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00176-9 · Cited by 299
MHAWECH, P. (2005) · Cell Research · doi:10.1038/sj.cr.7290291 · Cited by 301
Activation of GCN2 in UV-Irradiated Cells Inhibits Translation
Deng, J., Harding, H. P., Raught, B., Gingras, A.-C., Berlanga, J. J., Scheuner, D., Kaufman, R. J., Ron, D., & Sonenberg, N. (2002) · Current Biology · doi:10.1016/s0960-9822(02)01037-0 · Cited by 290
Modulation of Protein–Protein Interactions with Small Organic Molecules
Berg, T. (2003) · Angewandte Chemie International Edition · doi:10.1002/anie.200200558 · Cited by 292
miR-181a and miR-630 Regulate Cisplatin-Induced Cancer Cell Death
Galluzzi, L., Morselli, E., Vitale, I., Kepp, O., Senovilla, L., Criollo, A., Servant, N., Paccard, C., Hupé, P., Robert, T., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3112 · Cited by 280
Ito, K., Nakazato, T., Yamato, K., Miyakawa, Y., Yamada, T., Hozumi, N., Segawa, K., Ikeda, Y., & Kizaki, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1670 · Cited by 287
DNA Damage Response Genes and the Development of Cancer Metastasis
Broustas, C. G., & Lieberman, H. B. (2014) · Radiation Research · doi:10.1667/rr13515.1 · Cited by 275
“RAD17 DDR, cell cycle checkpoint — (187, 188) RAD51 HRR — (241) TIP60 DDR, DSBR — (285, 286) TP53 DDR Transcription factor, apoptosis (251, 256) XRCC3 NER — (243)”
BackgroundLi, H.-Y., Zhang, J., Sun, L.-L., Li, B.-H., Gao, H.-L., Xie, T., Zhang, N., & Ye, Z.-M. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.543 · Cited by 284
“In addition, p21 has an important role in G2/M checkpoint through inhibition of the Cdc2/cyclin B1 complex in a p53-dependent or independent manner.(16,42) As HOS is p53-mutant, it is most likely that upregulation of p21 was mediated in a p53-independent manner and the specific mechanism needs to be further explored.”
BackgroundStructural and Functional Changes and Possible Molecular Mechanisms in Aged Skin
Lee, H., Hong, Y., & Kim, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212489 · Cited by 243
Histone methylation and the DNA damage response
Gong, F., & Miller, K. M. (2019) · Mutation Research/Reviews in Mutation Research · doi:10.1016/j.mrrev.2017.09.003 · Cited by 248
Bohuslav, J., Chen, L.-F., Kwon, H., Mu, Y., & Greene, W. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m313509200 · Cited by 256
Liebermann, D. A., & Hoffman, B. (2008) · Journal of Molecular Signaling · doi:10.1186/1750-2187-3-15 · Cited by 238
“The ATM/p53 tumor suppressor pathway [17-19] and the p38/JNK kinase pathways [20-23] have recently been determined to play major roles as mediators of the mammalian response to genotoxic stress.”
The mechanism of non-homologous end-joining: a synopsis of synapsis
Weterings, E., & van Gent, D. C. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.06.003 · Cited by 230
DNA Damage, Repair, and Cancer Metabolism
Turgeon, M.-O., Perry, N. J. S., & Poulogiannis, G. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00015 · Cited by 241
“412 upon DNA damage or other cellular stress, p53 is activated by phosphorylation events that prevent its degradation (60).”
BackgroundApoptosis regulators and their role in tumorigenesis
Zörnig, M., Hueber, A.-O., Baum, W., & Evan, G. (2001) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/s0304-419x(01)00031-2 · Cited by 239
An inducible long noncoding RNA amplifies DNA damage signaling
Schmitt, A. M., Garcia, J. T., Hung, T., Flynn, R. A., Shen, Y., Qu, K., Payumo, A. Y., Peres-da-Silva, A., Broz, D. K., Baum, R., et al. (2016) · Nature Genetics · doi:10.1038/ng.3673 · Cited by 239
Chen, T., & Wong, Y.-S. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.014 · Cited by 231
Intrinsically Disordered Segments Affect Protein Half-Life in the Cell and during Evolution
van der Lee, R., Lang, B., Kruse, K., Gsponer, J., Sánchez de Groot, N., Huynen, M. A., Matouschek, A., Fuxreiter, M., & Babu, M. M. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.07.055 · Cited by 237
“, 1995), DNA repair (Lakin and Jackson, 1999), apoptosis and cell survival (Rutkowski et al.”
Histone deacetylase inhibitors and cell death
Zhang, J., & Zhong, Q. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1656-6 · Cited by 214
“Bax, Puma and Noxa) to induce apoptosis [122-127].”
Cell-Cycle Regulation of NF-YC Nuclear Localization
Frontini, M., Imbriano, C., Manni, I., & Mantovani, R. (2004) · Cell Cycle · doi:10.4161/cc.3.2.654 · Cited by 229
Ahmad, S. (2010) · Chemistry & Biodiversity · doi:10.1002/cbdv.200800340 · Cited by 215
BCR/ABL activates mdm2 mRNA translation via the La antigen
Trotta, R., Vignudelli, T., Candini, O., Intine, R. V., Pecorari, L., Guerzoni, C., Santilli, G., Byrom, M. W., Goldoni, S., Ford, L. P., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00020-5 · Cited by 217
“Expression of MDM2 tested upon treatment with adriamycin, a cytotoxic drug known to promote a transient increase in p53 levels by suppressing was barely detectable in parental cells (Figure 2A, lane 1), but markedly increased in 32D-BCR/ABL newly derived cell clones its degradation (Lakin and Jackson, 1999).”
Erdal, H., Berndtsson, M., Castro, J., Brunk, U., Shoshan, M. C., & Linder, S. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408592102 · Cited by 218
The role of p53 and pRB in apoptosis and cancer
Hickman, E. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(01)00265-9 · Cited by 214
Tumor Heterogeneity: A Great Barrier in the Age of Cancer Immunotherapy
El-Sayes, N., Vito, A., & Mossman, K. (2021) · Cancers · doi:10.3390/cancers13040806 · Cited by 193
“For example, in normal cells the tumor suppressor p53 responds to DNA damage by triggering pathways involved in cell-cycle arrest, apoptosis, or DNA repair [23].”
BackgroundResveratrol protects dopaminergic neurons in midbrain slice culture from multiple insults
Okawara, M., Katsuki, H., Kurimoto, E., Shibata, H., Kume, T., & Akaike, A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2006.11.003 · Cited by 200
“Lysine residues at the C-terminal region of p53 are acetylated in response to DNA damage, which leads to stabilization of p53 protein, recruitment of co-activators, and induction of apoptotic cell death [38].”
BackgroundMechanisms of apoptosis induction by nucleoside analogs
Sampath, D., Rao, V. A., & Plunkett, W. (2003) · Oncogene · doi:10.1038/sj.onc.1207229 · Cited by 199
“Members of the PI-3 kinase phosphorylate p53 and lead to its subsequent stabilization (Lees-Miller et al., Oncogene 1995; Lakin and Jackson, 1999; Tibbetts et al., 1999; Shiloh, 2001).”
BackgroundLead induces oxidative stress, DNA damage and alteration of p53, Bax and Bcl-2 expressions in mice
Xu, J., Lian, L.-J., Wu, C., Wang, X.-F., Fu, W.-Y., & Xu, L.-H. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2007.12.016 · Cited by 196
“This then leads to the activation of a number of genes and triggers cell-cycle arrest, apoptosis, or DNA repair (Lakin and Jackson, 1999).”
BackgroundTranscriptomic characterization of cold acclimation in larval zebrafish
Long, Y., Song, G., Yan, J., He, X., Li, Q., & Cui, Z. (2013) · BMC Genomics · doi:10.1186/1471-2164-14-612 · Cited by 191
“The p53 signaling pathway can be induced by stress signals such as DNA damage, hypoxia, heat and oxidative stress and its activation often leads to cell cycle arrest, cellular senescence or apoptosis [44-46].”
BackgroundIntrinsic ubiquitination activity of PCAF controls the stability of the oncoprotein Hdm2
Linares, L. K., Kiernan, R., Triboulet, R., Chable-Bessia, C., Latreille, D., Cuvier, O., Lacroix, M., Le Cam, L., Coux, O., & Benkirane, M. (2007) · Nature Cell Biology · doi:10.1038/ncb1545 · Cited by 180
“On genotoxic stress, p53 is activated by a complex process, often correlated with its rapid stabilizatio”
BackgroundHyperosmolality in the form of elevated NaCl but not urea causes DNA damage in murine kidney cells
Kültz, D., & Chakravarty, D. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.4.1999 · Cited by 188
Base Excision Repair Intermediates Induce p53-independent Cytotoxic and Genotoxic Responses
Sobol, R. W., Kartalou, M., Almeida, K. H., Joyce, D. F., Engelward, B. P., Horton, J. K., Prasad, R., Samson, L. D., & Wilson, S. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306592200 · Cited by 182
Checkpoints: How to activate p53
Caspari, T. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00439-5 · Cited by 184
“The discovery that ‘checkpoint’ pathways, which monitor the structural integrity of our chromosomes, stabilise and activate p53 in response to DNA damage indicated how these control systems act to protect organisms from the potentially harmful effects of damaged cells [1].”
REVIEW: Pin1 in Alzheimer's disease
Butterfield, D. A., Abdul, H. M., Opii, W., Newman, S. F., Joshi, G., Ansari, M. A., & Sultana, R. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03995.x · Cited by 179
“Conversely, we postulate that oxidative dysfunction of Pin1 (Sultana et al. 2005, 2006; Butterfield et al. 2006a) would lead to the loss to PP2A-mediated dephosphorylation of tau, with consequent neuronal dysfunction.”
BackgroundFernández-Salas, E., Suh, K. S., Speransky, V. V., Bowers, W. L., Levy, J. M., Adams, T., Pathak, K. R., Edwards, L. E., Hayes, D. D., Cheng, C., et al. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.11.3610-3620.2002 · Cited by 185
“The tumor suppressor protein p53 plays a central role in the elimination of cells with unregulated mitotic potential or DNA damage (9, 30, 42).”
Daver, N. G., Maiti, A., Kadia, T. M., Vyas, P., Majeti, R., Wei, A. H., Garcia-Manero, G., Craddock, C., Sallman, D. A., & Kantarjian, H. M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0332 · Cited by 166
“enable the induction of apoptosis (2, 3).”
BackgroundGali-Muhtasib, H., Kuester, D., Mawrin, C., Bajbouj, K., Diestel, A., Ocker, M., Habold, C., Foltzer-Jourdainne, C., Schoenfeld, P., Peters, B., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0884 · Cited by 170
Detorakis (2009) · International Journal of Molecular Medicine · doi:10.3892/ijmm_00000149 · Cited by 170
Karpf, A. R., Moore, B. C., Ririe, T. O., & Jones, D. A. (2001) · Molecular Pharmacology · doi:10.1016/s0026-895x(24)09243-5 · Cited by 176
“This observation is consistent with the fact that many chemotherapeutics are DNA-damaging agents and that p53 plays a critical role in the induction of cellular growth arrest and apoptosis in response to DNA damage (Lakin and Jackson, 1999).”
InfluentialProlyl isomerase Pin1: a catalyst for oncogenesis and a potential therapeutic target in cancer
Ryo, A., Liou, Y.-C., Lu, K. P., & Wulf, G. (2003) · Journal of Cell Science · doi:10.1242/jcs.00276 · Cited by 173
“It has become evident that phosphorylation-dependent prolyl isomerization is a previously uncharacterized postphosphorylation signaling mechanism in cell proliferation and transformation.”
BackgroundInfluentialChoi, M., Shi, J., Jung, S. H., Chen, X., & Cho, K.-H. (2012) · Science Signaling · doi:10.1126/scisignal.2003363 · Cited by 174
“Thus, it appears that increasing p53 activity above a certain threshold is sufficient to trigger cell death, independent of the p53 posttranslational modifications that are believed to rely on the DNA damage (47, 48).”
BackgroundFaces of cellular senescence in skin aging
Ho, C. Y., & Dreesen, O. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111525 · Cited by 158
“Induction of p53 and p21 also occurs upon DNA damage in cells undergoing transient cell cycle arrest (Karimian et al., 2016; Lakin and Jackson, 1999).”
BackgroundLai, Z., Ferry, K. V., Diamond, M. A., Wee, K. E., Kim, Y. B., Ma, J., Yang, T., Benfield, P. A., Copeland, R. A., & Auger, K. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m011517200 · Cited by 167
Exploring the multiple roles of guardian of the genome: P53
Feroz, W., & Sheikh, A. M. A. (2020) · Egyptian Journal of Medical Human Genetics · doi:10.1186/s43042-020-00089-x · Cited by 186
The tumour suppressor protein p53 can repress transcription of cyclin B
Krause, K. (2000) · Nucleic Acids Research · doi:10.1093/nar/28.22.4410 · Cited by 171
Focus on UV-Induced DNA Damage and Repair—Disease Relevance and Protective Strategies
Kciuk, M., Marciniak, B., Mojzych, M., & Kontek, R. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197264 · Cited by 168
“Furthermore, P21 inhibits CDKs preventing the phosphorylation of the retinoblastoma-associated protein (pRB), thereby disabling the G1 to the S transition of the cell cycle (Figure 6) [61,63,64].”
BackgroundDNA damage response pathway in radioadaptive response
Sasaki, M. S., Ejima, Y., Tachibana, A., Yamada, T., Ishizaki, K., Shimizu, T., & Nomura, T. (2002) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/s0027-5107(02)00084-2 · Cited by 171
Role of the p38 MAPK pathway in cisplatin-based therapy
Losa, J. H., Cobo, C. P., Viniegra, J. G., Lobo, V. J. S.-A., Cajal, S. R. Y., & Sánchez-Prieto, R. (2003) · Oncogene · doi:10.1038/sj.onc.1206608 · Cited by 166
“It is very well established that proteins like Abl (Kharbanda et al., 1998), DNAPK (Smith and Jackson, 1999), ATM (Khanna and Jackson, 2001) and p53 (Lakin and Jackson, 1999) are implicated in the response to chemo- and radiotherapy.”
BackgroundAn essential function for NBS1 in the prevention of ataxia and cerebellar defects
Frappart, P.-O., Tong, W.-M., Demuth, I., Radovanovic, I., Herceg, Z., Aguzzi, A., Digweed, M., & Wang, Z.-Q. (2005) · Nature Medicine · doi:10.1038/nm1228 · Cited by 164
“The mechanism underlying this phenotype may be explained by a high basal level of chromosomal aberrations in Nbn -deficient neural cells which activates the DNA damage checkpoint response and leading to cell cycle arres”
BackgroundHercog, K., Maisanaba, S., Filipič, M., Dolenc, M. S., Kač, L., & Žegura, B. (2019) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2019.05.486 · Cited by 165
Pifithrin-α protects against doxorubicin-induced apoptosis and acute cardiotoxicity in mice
Liu, X., Chua, C. C., Gao, J., Chen, Z., Landy, C. L. C., Hamdy, R., & Chua, B. H. L. (2004) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00759.2003 · Cited by 162
“Our results suggest that phosphorylation of p53, which is known to play an important role in p53 transactivation activity (13, 20, 21), increases the upregulation of Bax gene expression.”
BackgroundMayr, M., Hu, Y., Hainaut, P., & Xu, Q. (2002) · The FASEB Journal · doi:10.1096/fj.02-0042fje · Cited by 155
Discrimination of genotoxic from non-genotoxic carcinogens by gene expression profiling
van Delft, J. H. M. (2004) · Carcinogenesis · doi:10.1093/carcin/bgh108 · Cited by 158
In vitro biocompatibility of mesoporous metal (III; Fe, Al, Cr) trimesate MOF nanocarriers
Grall, R., Hidalgo, T., Delić, J., Márquez, A. G., Chevillard, S., & Horcajada, P. (2015) · Journal of Materials Chemistry B · doi:10.1039/c5tb01223f · Cited by 164
Lopez-Borges, S., & Lazo, P. A. (2000) · Oncogene · doi:10.1038/sj.onc.1203709 · Cited by 159
“These phosphorylations occur in response to speci®c types of stimulation (Meek, 1999), such as DNA damage (Lakin et al., 1999; Lakin and Jackson, 1999; Shieh et al., 1997; Siliciano et al., 1997).”
BackgroundAtherosclerosis Is a Smooth Muscle Cell–Driven Tumor-Like Disease
Pan, H., Ho, S. E., Xue, C., Cui, J. G., Johanson, Q., Sachs, N., Ross, L. S., Li, F., Solomon, R. A., Connolly, E. S., et al. (2024) · Circulation · doi:10.1161/circulationaha.123.067587 · Cited by 165
Early stages of p53-induced apoptosis are reversible
Geske, F. J., Lieberman, R., Strange, R., & Gerschenson, L. E. (2001) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4400786 · Cited by 159
Regulation and Pathological Role of p53 in Cisplatin Nephrotoxicity
Jiang, M., & Dong, Z. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.139162 · Cited by 162
“The protein kinases that have been identified include ATM, ATR, DNA-PK, ChK, protein kinase C, CDK, mitogen-activated protein kinase, casein kinases I and II (Lakin and Jackson, 1999; Shiloh, 2003; Bode and Dong, 2004).”
Novel Mode of Action of Tylophorine Analogs as Antitumor Compounds
Gao, W., Lam, W., Zhong, S., Kaczmarek, C. G., Baker, D. C., & Cheng, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1904 · Cited by 153
“In addition, p53 activation has also been implicated in triggering cell cycle arrest, including both the G1 and G2 phases of the cell cycle (34).”
BackgroundCanon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., Eksterowicz, J., Ye, Q., Jin, L., Chen, A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0710 · Cited by 152
“the p53 pathway (18), which leads to growth arrest and apoptosis.”
BackgroundCancer signaling, cell/gene therapy, diagnosis and role of nanobiomaterials
Rosic, G. L. (2024) · Advances in Biology & Earth Sciences · doi:10.62476/abes9s11 · Cited by 163
Arima, Y., Hirota, T., Bronner, C., Mousli, M., Fujiwara, T., Niwa, S., Ishikawa, H., & Saya, H. (2004) · Genes to Cells · doi:10.1111/j.1356-9597.2004.00710.x · Cited by 142
“G1 arrest after DNA damage is induced primarily by stabilization of the p53 tumour suppressor protein (Lakin & Jackson 1999). p53 is activated and post-translationally modified in response to DNA damage.”
Background
Metadata
- Authors
- Lakin, N. D., & Jackson, S. P.
- Affiliations
- University of Cambridge (GB)
- ORCID
- Jackson, Stephen P
- Venue
- Oncogene
- Published
- 1999-12-13
- Volume
- 18
- Issue
- 53
- Pages
- 7644-7655
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2007935491
- Cited by
- 987
- References
- 128
- Citations by year
- 2026: 18 · 2025: 29 · 2024: 30 · 2023: 54 · 2022: 57 · 2021: 46 · 2020: 46 · 2019: 33 · 2018: 40 · 2017: 43 · 2016: 34 · 2015: 33 · 2014: 28 · 2013: 23 · 2012: 28
- FWCI
- 4.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Heat shock proteins research
- Keywords
- p53, DNA damage response, p53 activation, post-translational modification, phosphorylation, dephosphorylation, acetylation, ionizing radiation, ultraviolet radiation, methyl methanesulfonate, cell cycle arrest, apoptosis, DNA repair, transcriptional activation, hypoxia
- MeSH terms
- Adenosine Triphosphatases, Animals, DNA Damage, DNA Helicases, DNA-Binding Proteins, Humans, Nuclear Proteins, Protein Processing, Post-Translational, Proto-Oncogene Proteins, Signal Transduction, Trans-Activators, Tumor Suppressor Protein p53, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Tumor Suppressor Proteins, Saccharomyces cerevisiae Proteins, Proto-Oncogene Proteins c-mdm2, DNA-Activated Protein Kinase, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.